Emil D. Kakkis - Mar 1, 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
President & CEO, Director
Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Mar 1, 2023
Transactions value $
-$736,791
Form type
4
Date filed
3/3/2023, 06:52 PM
Previous filing
Jan 3, 2023
Next filing
Oct 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Award $0 +8.72K +1.55% $0.00 569K Mar 1, 2023 Direct F1
transaction RARE Common Stock Award $0 +46.2K +8.11% $0.00 616K Mar 1, 2023 Direct F2
transaction RARE Common Stock Tax liability -$737K -16.1K -2.62% $45.65 599K Mar 1, 2023 Direct F3, F4, F5
holding RARE Common Stock 2.26M Mar 1, 2023 By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RARE Stock Option (Right to Buy) Award $0 +83.5K $0.00 83.5K Mar 1, 2023 Common Stock 83.5K $45.65 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric.
F2 Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
F3 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
F4 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F5 Reflects transfer of directly owned shares of common stock from the Reporting Person to a trust indirectly held by the Reporting Person that have taken place since the most recent prior report on Form 4.
F6 On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

Remarks:

This Form 4 corrects an error made in the Reporting Person's prior most recent Form 4 which reflected a sale that occurred from his individual account, rather than from his trust account. The amounts set forth in Table I, Column 6 of this Form 4 reflect the corrected amounts that are directly and indirectly beneficially owned by the Reporting Person.